

**NCCN Non-Melanoma Guidelines (Basal Cell and Squamous Cell Skin Cancer) V.1.2011
– Update Teleconference – 11/15/10**

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p><u>Basal Cell Skin Cancer</u> BCC-4</p> <p>Internal request: Review the data for the combination chemotherapy drugs listed in footnote k for the treatment of regional or distant metastatic basal cell skin cancer (cisplatin and cyclophosphamide, cisplatin and vinblastine, cisplatin and doxorubicin, cisplatin and paclitaxel).</p>	<p>Footnote “k” formerly read: “Clinical trials of chemotherapy or biologic modifiers are recommended for metastatic basal cell carcinoma. Combination chemotherapy has produced useful responses (cisplatin and cyclophosphamide, cisplatin and vinblastine, cisplatin and doxorubicin, cisplatin and paclitaxel).” Based on the literature and discussion, the panel consensus was to change footnote “k” to read: “Clinical trials of chemotherapy or hedgehog inhibitors are recommended for metastatic basal cell carcinoma. Combination chemotherapy with cisplatin- or carboplatin-based doublets has produced useful responses.”</p>	<p>Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-1172. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19726763.</p>	13	0	0
<p><u>Squamous Cell Skin Cancer</u> SCC-7</p> <p>Internal request: Remove doxorubicin and bleomycin from statement in footnote “p” regarding the treatment of regional recurrence or distant metastatic squamous cell skin cancer.</p>	<p>The last sentence in footnote “p” formerly read: “Cisplatin either as single agent or combined with 5-FU, doxorubicin, or bleomycin have occasionally produced useful responses, but data supporting efficacy are limited.” Based on lack of data to support use, the panel consensus was to remove doxorubicin and bleomycin from footnote “p”.</p>		13	0	0